The current COVID-19 pandemic illustrates how vulnerable the world is to viral infections. There is a strategic need for new approaches to treat patients exposed to viruses without creating drug resistance and protect high-risk patients. A new class of antiviral drugs is needed to change the paradigm from having “one drug against one virus” to “one drug against multiple viruses. Our mission is to develop and commercialize our small molecule platform of broad-spectrum antiviral drugs to overcome the clinical challenge of current and future viral infections via a single mechanism rather than the current piecemeal approach to individual viruses. Our lead drug candidate, GPS-491, blocks the replication of important viruses with unmet clinical needs- Herpes, HIV, adenovirus, coronaviruses, and other known and new emerging viruses. GPS-491 modulates RNA processing and is highly effective against SARS-CoV2 and common circulating coronaviruses. The multiple emerging COVID-19 variants, which pose a risk for vaccine failure, require RNA processing and therefore, will retain GPS-491 sensitivity.